Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Uterine Cervical Neoplasms 3Vaginal Neoplasms 2Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Pdgfra-Associated Chronic Eosinophilic Leukemia 1Neuroendocrine Tumors 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Accelerated Phase 1Gallbladder Neoplasms 1Blast Crisis 1

Interventions

fludarabine phosphate 15Whole-Body Irradiation 9Peripheral Blood Stem Cell Transplantation 9Mycophenolic Acid 9Cyclophosphamide 8Busulfan 8Tacrolimus 7Cyclosporine 5ruxolitinib 4fludarabine 4Methotrexate 4Antilymphocyte Serum 411-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3peginterferon alfa-2a 2givinostat hydrochloride 2givinostat 2Stem Cell Transplantation 2Radiotherapy 2Melphalan 2Etoposide 2Carboplatin 2veliparib 1thymoglobulin 1sonidegib 1pomalidomide 1merphos 1bomedemstat 1anagrelide 1Transplantation 1Topotecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Thrombocythemia, Essential × 3-aminopyridine-2-carboxaldehyde thiosemicarbazone × Clear all
NCT00381550 2015-01-06

3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia

National Cancer Institute (NCI)

Phase 2 Completed
35 enrolled 8 charts
MyeloidOther hematologic neoplasm

Pdgfra-Associated Chronic Eosinophilic Leukemia, Blast Crisis, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡